A case report of placental mesenchymal dysplasia
A rare case of a genetically normal fetus with severe intrauterine growth restriction

Bogdan Doroftei, MD, PhD⁎,⁎⁎, Sabina Neculaie-Valeanu, DVM⁎⁎⁎, Gabriela Simionescu, MD, PhD⁎⁎⁎⁎, Delia Grab, MD, PhD⁎⁎⁎⁎, Natalia Popa, MD, PhD⁎⁎⁎⁎, Emil Anton, MD⁎⁎⁎⁎, Radu Maftei, MD, PhD⁎⁎⁎⁎

Abstract
Rationale: We report a rare case of a pregnant woman with placental mesenchymal dysplasia (PMD) and intrauterine growth restriction (IUGR) with a genetically normal fetus.

Patient concerns: A 42-year-old woman Gravida I, Para I with pre-existent uncontrolled hypertension and uterine polyfibromatosis present at 30 weeks of gestation for diminished fetal activity during the last 2 days.

Diagnosis: Placental mesenchymal dysplasia associated with intrauterine growth restriction, hypertension, and uterine polyfibromatosis.

Intervention: A live male infant was delivered by emergency cesarean section.

Outcomes: The infant, weighing 700 g, died 4 days after birth due to a massive intracerebral hemorrhage.

Lessons: A careful examination should be done at every ultrasound in case of a fetus with IUGR to exclude some rare cases of placental pathologies. PMD can be a rare cause of IUGR with a genetically normal fetus.

Abbreviations: AFI = amniotic fluid index, BMI = body mass index, BWS = Beckwith-Wiedemann syndrome, CRL = crown rump length, IGF-2 = insulin-like growth factor 2, IUFD = intrauterine fetal demise, IUGR = intrauterine growth restriction, NT = nuchal translucency, PMD = placental mesenchymal dysplasia, VEGF-D = vascular endothelial growth factor D.

Keywords: Beckwith-Wiedemann syndrome, intrauterine fetal growth restriction, molar pregnancy, placental mesenchymal dysplasia

1. Introduction
Placental mesenchymal dysplasia (PMD) is a rare benign disorder of the placenta characterized by placentalomegaly and grapelike vesicles that can resemble at ultrasound examination with a molar pregnancy.[1] PMD was described initially by Moscoso et al.[2] as stem villous hyperplasia with elevated maternal serum alpha-feto-protein and enlarged placentas with ultrasound features that are suggestive of partial mole. This condition may resemble a partial hydatidiform mole, however in contrast to partial mole trophoblastic proliferation is absent, the disorder being characterized by aneuryral dilatation of vessels on the fetal surface of the placenta with dilated stem villi. Although there are some papers that report an incidence around 0.02% of pregnancies,[3] the true incidence of PMD is unknown because it has been previously reported under a variety of names such as “placentalomegaly with massive hydrops of placental stem villi” and “pseudopartial moles.”[4,5] Moreover, placental mesenchymal dysplasia is associated with fetal growth restriction (IUGR) in the majority of the cases and in approximately one quarter of the reported cases with Beckwith-Wiedemann syndrome (BWS)[4,6] or intrauterine fetal demise (IUFD), but can also be associated with normal appearing fetuses.

2. Case report
We report the case of a 42-year-old woman, Gravida 1, Para 1, that presented to the hospital due to diminished fetal activity in July 2017. Before obtaining this spontaneous pregnancy, the patient was previously diagnosed with a history of almost 10 years of infertility, uterine polyfibromatosis, hypertension, and obesity grade II. The first ultrasound was performed at 11 weeks and 6 days and revealed a single intrauterine pregnancy. The following parameters were determined during the ultrasound exam: crown rump length (CRL) (51.8 mm), nuchal translucency (1.3 mm), nasal bone present, and ductus venosus flow (Fig. 1). Patient underwent a noninvasive prenatal test and the results were: “low risk”, sex male fetus, and a 4.1% fetal fraction.

Further on, the physical examination of the patient revealed that the patient measured 170 cm in height and 113 kg in weight, having a body mass index (BMI) of 39.1. The blood pressure was 140/90 mmHg thereby the patient was advised to undergo a
cardiologic examination in order to change the treatment for the pre-existing hypertension. Unlike the second trimester morphology, which was performed at 21 weeks and had normal results, the ultrasound examination performed at 30 weeks showed severe IUGR (780 g) <2.9 percentile, oligoamnios (amniotic fluid index—AFI: 7), ductus venosus with a negative wave, umbilical artery with reversed diastolic flow and placentomegaly with multicystic appearance without vascular flow (Fig. 2).

Figure 1. Ultrasound examination at 11 weeks showing a normal appearance of the placenta, normal ductus venosus flow, and CRL corresponding to gestational age. CRL = crown rump length.

Figure 2. A: ductus venosus with negative a wave; B–D: placentomegaly with multicystic appearance without vascular flow.
Due to these findings, the patient was referred in emergency to the department of obstetrics and gynecology of Cuza Voda Clinical Hospital. At hospital admission, blood pressure was 160/110 mmHg and the medical team initiated treatment with Dopegyt 1tb/6h and Nifedipine 1tb/12h. Non-stress test was performed and revealed low reactivity, thereby an amniocentesis was performed and treatment with dexamethasone 6mg/12h was initiated. Subsequently, after 48 hours a C-section was performed resulting a male fetus with normal appearance, weighting 700g, APGAR score 3. The result from amniocentesis confirmed the absence of genetic anomalies, but the fetus died 4 days later after a massive intracerebral hemorrhage.

Table 1

| Time interval | Diagnosis | Intervention/recommendations |
|---------------|-----------|------------------------------|
| Infertility evaluation | Beginning of 2016 | Primary infertility | Nutritional consult for weight loss |
| Pregnancy confirmation | Autumn 2016 | Spontaneous pregnancy confirmed at another medical center | Hormonal profile |
| 11 weeks of pregnancy | December 2016 | Single intrauterine pregnancy, normal development; Noninvasive prenatal test | Cardiologic consult change the treatment for the pre-existing hypertension (blood pressure was 140/90 mmHg) |
| 17 weeks of pregnancy | January 2017 | Normal results | Address a nutritionist to monitor taken into account the patient’s BMI (39.1) |
| Second trimester morphology (performed at 21 weeks) | February 2017 | Normal results | The prenatal test results were low risk; male fetus |
| 30 weeks checkout | May 2017 | Severe IUGR (780 g) <2.0 percentile, oligoamnios (amniotic fluid index—AFI: 7), ductus venosus with a negative wave, umbilical artery with reversed diastolic flow and placenomegaly with multi cystic appearance without vascular flow | Referred in emergency to the department of obstetrics and gynecology of Cuza Voda Clinical Hospital; blood pressure was 160/110 mmHg |
| 48 h after hospital admission | | Performed C-section and delivered a male fetus with normal appearance, weighting 700g, APGAR score 3 | initiated treatment with Dopegyt 1tb/6h and Nifedipine 1tb/12h non-stress test with low reactivity; amniocentesis |
| | | | initiated treatment with dexamethasone 6mg/12h was initiated |
| | | | The result from amniocentesis confirmed the absence of genetic anomalies, |
| | | | The fetus died 4 days later after a massive intra-cerebral hemorrhage |

APGAR = Appearance, Pulse, Grimace, Activity, Respiration.

Figure 3. Gross image of enlarged placenta with multiple grape-like vesicles at maternal surface, especially around the cord insertion.

Figure 4. Microscopic image of placenta showing the presence of myxoid stroma and hydropic villi.

Placental mesenchymal dysplasia (PMD) is a rare benign condition with unknown underlying cause. It has been some theories that PMD is a congenital malformation of the mesoderm due to mesenchymal hyperplasia in stem villi. The enlarged stem villi contain acid mucopolysaccharide, which is found in the connective tissue layers of the normal chorionic mesoderm. Moreover, the most common karyotype associated with PMD, according to Truc et al, is 46,XX in 82% of cases and 20% of
cases also have BWS but, Kaiser-Rogers et al[9] proposed an androgenetic/biparental mosaicism as the etiological factor. Other type of genetic alterations found in PMD are: 11p15.5, which may affect the expression of IGF-2[5] and Xp22.31, which is expressed as vascular endothelial growth factor D (VEGF-D).[10]

The incidence of this pathology is reported to be around 0.02% of pregnancies[3] with a preponderance of 3.6–4/1 female/male.[11,12] The sex of the fetus is another particularity of the case. In our case the fetus was normal (46, XY) but Cohen et al[13] described 3 cases of PMD associated with fetal aneuploidy: trisomy 13 (47,XX, t(1:3) (q32;q32)+ 13), Klinefelter syndrome (47, XXY), and triploidy (69, XXX).

It is highly important to distinguish PMD from a partial mole with an abnormal triploid fetus, because this diagnosis may result in pregnancy termination while fetus from pregnancy with PMD may develop normally without severe maternal complications. The sonographic features of PMD are very similar to those of partial moles[13] and usually evidenced between 17 and 20 weeks of gestation or sometimes in the third trimester of pregnancy if the progressive development of vascular malformations secondary to circulatory disorders of the dysplastic villi is slow. Sonographic findings of PMD revealed a thickened placenta with multicystic appearance without vascular flow.[14] The umbilical cord anomaly may be found like single umbilical artery, excessively long cord, marked twisted cord, and abnormal insertion like eccentrically insertion which was observed in our case.

The etiology of intrauterine growth restriction comprise: infections, placental insufficiency and other type of pathology (chorioangioma, PMD), hypertension, genetic anomalies, uterine pathology, and age. In this case is very difficult to say the exact etiology of the IUGR because the patient has 4 factors for intrauterine growth restriction: age, polyfibromatosis, hypertension, and PMD. Late apparition of the growth restriction as well as PMD ultrasound images takes us to the supposition that PMD is the cause of growth restriction. The exact incidence of IUGR in pregnancies with PMD is unknown. Pham et al[10] reported, in a small cohort of 11 cases, a incidence of IUGR around 50% and intrauterine fetal demise around 43%.

According to Faye-Petersen fetuses and newborns with PMD are at risk for fetomaternal hemorrhage[15] that’s why we suppose that in this case the intracerebral hemorrhage may be due to PMD rather than prematurity.

4. Conclusions

The particularity of this case is the late development of the PMD and the severe IUGR with neonatal fetal death due to intracerebral hemorrhage. The severe growth restriction may also be in conjunction with the advanced maternal age and associated pathology (uterine poly-fibromatosis, hypertension, and obesity grade II). Another particularity is that the fetus was male and without any genetic anomaly.
In conclusion, we would like to emphasize on the importance of evaluating the placenta at every ultrasound examination because PMD has high rates of IUGR and IUFD and it is very important to identify it prenatally in an effort to reduce fetal morbidity and mortality.

Author contributions
Conceptualization: Bogdan Doroftei, Natalia Plopa, Emil Anton, Radu Maftei.
Investigation: Bogdan Doroftei, Gabriela Simionescu, Delia Grab, Emil Anton.
Methodology: Bogdan Doroftei.
Resources: Bogdan Doroftei.
Supervision: Bogdan Doroftei, Sabina Neculai-Valeanu.
Validation: Bogdan Doroftei.
Visualization: Gabriela Simionescu.
Writing – original draft: Bogdan Doroftei, Sabina Neculai-Valeanu, Natalia Plopa, Emil Anton, Radu Maftei.
Writing – review & editing: Bogdan Doroftei, Sabina Neculai-Valeanu, Gabriela Simionescu, Delia Grab, Radu Maftei.

References
[1] Parveen Z, Tongson-Ignacio JE, Frasier CR, et al. Placental mesenchymal dysplasia. Arch Pathol Lab Med 2007;131:131–7.
[2] Moscoso G, Jauniaux E, Huston J. Placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia: new clinico-pathological entity? Pathol Res Pract 1991;187:324–8.
[3] Arizawa M, Nakayama M. Suspected involvement of the X chromosome in placental mesenchymal dysplasia. Congenit Anom 2002;42:309–17.
[4] Lage JM. Placentomegaly with massive hydrops of placental stem villi, diploid DNA content and fetal omphalocele: possible association with Beckwith-Wiedemann syndromes. Hum Pathol 1991;22:591–7.
[5] Paradinas FJ, Sebire NJ, Fisher RA, et al. Pseudopartial moles placental stem vessel hydrops and the association with Beckwith Wiedemann syndrome and complete moles. Histo Pathol 2001;39:447–54.
[6] Jauniaux E, Nikolaides KH, Huston J. Perinatal features associated with placental mesenchymal dysplasia. Placenta 1997;18:701–6.
[7] Chen CP, Chorno SR, Wang FY, et al. Pregnancy with concomitant chorangioma and placental vascular malformation with mesenchymal hyperplasia. Hum Reprod 1997;12:2553–6.
[8] Truc P, Julie S, Carla S. Placental Mesenchymal Dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol 2006;126:67–78.
[9] Kaurer-Rogers KA, McFadden DE, Livasy CA, et al. Androgenetic/biparental mosaicism causes placental mesenchymal dysplasia. J Med Genet 2006;43:187–92.
[10] Pham T, Steele J, Staybeldt C, et al. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol 2006;126:67–78.
[11] Ohiura S, Ookubo N, Kobara H, et al. Placental mesenchymal dysplasia: chronological observation of placental images during gestation and review of the literature. Gynecol Obstet Invest 2013;75:217–23.
[12] Faye-Petersen OM, Kapur RP. Placental mesenchymal. Surg Pathol 2013;6:127–51.
[13] Cohen M, Roper E, Sebire NJ, et al. Placental mesenchymal dysplasia associated with fetal aneuploidy. Prenat Diagnosis 2005;25:187–92.
[14] Mittal D, Anand R, Soodia N, et al. Placental mesenchymal dysplasia: what every radiologist needs to know. Indian J Radiol Imaging 2017;27:62–4.
[15] Faye-Petersen OM, Kapur RP. Placental mesenchymal dysplasia. Surg Path Clin 2013;6:127–51.